Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry
AuthorsFurst, Daniel E.
Pangan, Aileen L.
Harrold, Leslie R.
Reed, George W.
Greenberg, Jeffrey D.
UMass Chan AffiliationsDepartment of Medicine, Division of Preventive and Behavorial Medicine
Department of Medicine, Division of Rheumatology
Meyers Primary Care Institute
Document TypeJournal Article
Tumor Necrosis Factor-alpha
Health Services Research
MetadataShow full item record
AbstractOBJECTIVE: To examine whether disease duration is an independent predictor of achieving remission in rheumatoid arthritis (RA) patients initiating therapy. METHODS: RA patients in the Consortium of Rheumatology Researchers of North America registry newly prescribed a nonbiologic disease-modifying antirheumatic drug (DMARD) or anti--tumor necrosis factor (anti-TNF) with at least one followup visit were identified. RESULTS: Among the 1,646 nonbiologic DMARD initiators, CDAI remission occurred in 21.3% of those with ≤5 years of disease duration, 19.6% with 6-10 years, and 13.5% with greater than or equal to 11 years (P < 0.001); sustained remission occurred in 10.2%, 8.8%, and 2.5%, respectively (P < 0.001). Results were similar among the 3,179 anti-TNF initiators (CDAI remission in 22.3%, 17.7%, and 12.8%, respectively [P < 0.001]; CDAI sustained remission in 9.7%, 9.5%, and 4.2%, respectively [P < 0.001]). DAS28 results were similar in both groups. In adjusted analyses, an increase of disease duration by 5 years was associated with a reduced likelihood of CDAI remission in nonbiologic DMARD (odds ratio [OR] 0.91, 95% confidence interval [95% CI] 0.83-0.99) and anti-TNF initiators (OR 0.88, 95% CI 0.83-0.94). A similar result was seen for sustained remission using the CDAI (nonbiologic DMARD: OR 0.61, 95% CI 0.48-0.76; anti-TNF: OR 0.85, 95% CI 0.75-0.97). CONCLUSION: Earlier treatment was associated with a greater likelihood of remission.
SourceArthritis Care Res (Hoboken). 2011 Jun;63(6):856-64. doi: 10.1002/acr.20452. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/37135
Related ResourcesLink to Article in PubMed